Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983249 | 0.77 | BACE1 (0.56) | BACE1NOS1GRM2LMNASMN1; SMN2 | |
| SCHEMBL31020164 | 0.75 | GRM2 (0.40) | BACE1NOS1GRM2LMNASMN1; SMN2 | |
| SCHEMBL12737722 | 0.70 | BACE1 (0.48) | BACE1NOS1GRM2LMNASMN1; SMN2 | |
| SCHEMBL5245198 | 0.68 | KDM4E (0.55) | LMNANPC1RAB9ANQO2 | |
| SCHEMBL339928 | 0.68 | BACE1 (0.63) | BACE1NOS1GRM2LMNASMN1; SMN2 | |
| SCHEMBL30657716 | 0.68 | BACE1 (0.63) | BACE1NOS1GRM2LMNASMN1; SMN2 | |
| SCHEMBL5845733 | 0.68 | ALDH1A1 (0.43) | NQO2 | |
| SCHEMBL28573272 | 0.68 | ALDH1A1 (0.56) | BACE1LMNANPC1RAB9ANQO2 | |
| SCHEMBL5201100 | 0.67 | BACE1 (0.41) | BACE1NOS1LMNASMN1; SMN2ENPP3 | |
| SCHEMBL3713340 | 0.67 | BACE1 (0.41) | BACE1NOS1GRM2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951880-B2 | Aryl and heteroaryl compounds as antibacterial and antifungal agents | GENELABS TECHNOLOGIES, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1417207-B1 | PROCESS FOR PREPARING 2-(4-PYRIDYL) AMINO-6-DIALKYLOXYPHENYL-PYRIDO(2,3-D)PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6900316-B2 | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin-7-ones | WARNER-LAMBER COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2004047724-A2 | ARYL AND HETEROARYL COMPOUNDS AS ANTIBACTERIAL AND ANTIFUNGAL AGENTS | GENELABS TECHNOLOGIES, INC (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030220340-A1 | Aryl and heteroaryl compounds as antibacterial and antifungal agents | GLAXOSMITHKLINE LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030176700-A1 | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin-7-ones | TJIONG HOWARD ISAAC (US) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176700-A1 | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin-7-ones | DPYD, PDXK, AHR | BACE1 4157/4885NOS1 4454/4885GRM2 2130/4885 |
| US-20030220340-A1 | Aryl and heteroaryl compounds as antibacterial and antifungal agents | AADAC, ERG28, LSS | BACE1 1939/4885NOS1 4057/4885GRM2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.